Zuellig Pharma has opened its new innovation centre in South Korea for supporting both domestic and worldwide clinical research needs.
The 3,800m² Clinical Trial Support (CTS) Innovation Center is set to serve as an advanced automated hub for clinical logistics and sourcing in South Korea.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The facility is located near the Gyeongbu Expressway in Gyeonggi-do province and aims to improve operational reliability and scalability in clinical trial logistics through digitalisation and automation while maintaining stringent Good Practice (GxP) compliance.
It includes a fully automated order fulfilment system designed to increase the speed and accuracy of clinical supply delivery.
The centre’s scalable infrastructure supports uninterrupted operations, while cybersecurity measures protect sensitive trial data.
It also offers comprehensive temperature-zone support, managing several clinical trial stock-keeping units (SKUs) under deep frozen, frozen, cold, ambient, return storage, and cryogenic conditions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSpecialised repackaging infrastructure of the facility allows for controlled environments suited to frozen, cold, ambient, and amber light specifications, ensuring compliance with regulatory and clinical standards.
The centre also features an integrated end-to-end monitoring and tracking system that enables traceability and complete chain-of-custody, reinforcing adherence to GxP requirements.
Zuellig Pharma CEO John Graham said: “As part of an integrated healthcare solutions company, this milestone marks a significant step forward for Zuellig Pharma in remaining agile and responsive to the evolving clinical trial landscape.
“It also reflects Zuellig Pharma’s continued commitment to advancing healthcare through innovation and sustainable infrastructure, creating greater access to treatments and delivering meaningful outcomes for partners and communities we serve.”
In the past year, the facility has supported more than 3,000 cumulative trials with over 100 clients, managing 13,000 outbound shipments annually.
